The US Department of Health and Human Services (HSS) signed a deal with Gilead Sciences to secure 500,000 treatment courses of remdesivir to treat Covid-19 patients.

According to a HHS release, this represents 100% of Gilead’s projected production for July and 90% for both August and September. The drug has been priced at $3,200 per treatment course of six doses, which slightly higher than the $2,340 price Gilead said a treatment course per patient would be in the developed countries.

This decision by the US means that the rest of the world will have very limited access to remdesivir, which is one of only two drugs proven to be effective against Covid-19. THis move demonstrates the extent to which the US is engaging in drug nationalism in the ongoing coronavirus pandemic.

HHS Secretary Alex Azar commented: “President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19.”

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it.

“The Trump Administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.